Nearly 50 Pharmaceutical Companies Raise RMB 19.3 Billion in New Financing Round
VelaVigo
Innovative Drug Developer
AusperBio
Biological Vaccine and Nucleic Acid Drug Developer
In December 2024, nearly 50 pharmaceutical companies worldwide completed a new round of financing, with a total amount of nearly 19.3 billion yuan.
Image Source: Pharma Data Enterprise Edition - Investment Landscape Database
Note: The exchange rates involved in the table are calculated based on the exchange rate at the time of financing completion.
Among them, several domestic companies completed billion-yuan financing in December.
Tianjin Nankai Hecheng S&T Co., Ltd. Completes 200 Million Yuan Equity Financing, Continues to Expand Competitive Advantage in Functional Polymer Resins Field
On December 31, Tianjin Nankai Hecheng S&T Co., Ltd., a key global supplier of solid-phase synthesis carrier resins, completed a 200 million yuan B round of financing, led by Shenzhen Capital Group. BMD Capital served as the exclusive financial advisor for this round of financing.
This round of financing is mainly used for the subsequent capacity construction of Tianjin Nankai Hecheng S&T Co., Ltd. and the expansion and improvement of the company's talent team. After this round of financing, Tianjin Nankai Hecheng S&T Co., Ltd. will continue to be based on efficient, stable, and high-quality large-scale production, with continuous growth in research and development and sales as the expansion. In the future, it will further consolidate and expand its presence in both domestic and international markets, striving to become a comprehensive leading enterprise in the global functional polymer resin field.
Orange Sail Pharmaceuticals Completes Nearly 50 Million USD Pre-A Financing Round, Accelerating the Development of Differentiated Innovative Treatment Solutions
On December 31, AusperBio announced the completion of a nearly 50 million USD Pre-A round of financing. This round was led by Panacea Venture (Panacea Healthcare) and Shanghai Biomedical Fund, with continued support from existing shareholder HLC (Hillhouse Capital), and participation from multiple well-known investment institutions including Everjoy Fortune, Wanwu Ventures, Delian Capital, and Legend Star.
This round of financing will be used to advance Orange Sails Pharma's innovative drug pipeline, accelerate core R&D projects into the clinical development stage, and focus on developing differentiated innovative therapeutic solutions for areas such as oncology and autoimmune diseases.
Ruifeng Biosciences Completes Hundreds of Millions in Financing to Advance Gene Editing Innovative Drug Development
On December 30, Refine Bio announced the successful completion of a new round of financing worth hundreds of millions of RMB. This round was led by Guangzhou Industrial Investment, with participation from Guangzhou Finance Holdings, Kejin Holdings, and existing shareholder GZYY Capital, among other institutions.
The funds from this financing will be mainly used to advance Ruifeng Biologics' gene-editing drug clinical trials, subsequent R&D pipeline expansion, and core technology innovation.
AusperBio Completes $73 Million Series B Financing to Accelerate Global Development of Hepatitis B Cure AHB-137
On December 27, AusperBio, an innovative drug research and development company in the small nucleic acid field, announced the completion of a $73 million Series B financing round. This round was led by Hanking Capital, with participation from Sherpa Healthcare Partners, CDH VGC, and a globally renowned industrial investment institution. Additionally, previous investors Qiming Venture Partners, InnoPinnacle Fund, and Vivo Capital also contributed follow-on investments.
This round of financing will mainly be used to advance the clinical trials of AHB-137, AusperBio's core small nucleic acid innovative drug, in China and internationally, as well as to prepare for its early commercialization. In addition, the funds will also support the expansion of the company’s new R&D pipeline and the ongoing development and growth of the team.
AusperBio Completes 200 Million Yuan Financing, Post-Investment Valuation at 3.2 Billion Yuan
On December 25, Huahai Pharmaceutical announced that its subsidiary, Huao Tai Bio (AusperBio), had completed a 200 million yuan financing round, exclusively invested by Haizheng Venture Capital.
The repurchase clause reveals Huaotai Bio's operational goals for the next 3-5 years, including obtaining approval for one product within 3 years, initiating pivotal Phase III clinical trials for another product, advancing a third product into Phase II/III clinical trials, securing approval for two products within 5 years, advancing two more products into Phase II/III clinical trials, and achieving an IPO within the agreed timeframe.
Yiming Biotech Completes Nearly 200 Million Yuan in New Strategic Financing to Support Commercial Production of ATMPs CDMO
On December 24, Yiming Biotech announced the successful completion of a new round of strategic financing worth nearly 200 million RMB. This round of financing was jointly invested by the Beijing Changping Industrial Development Investment Fund and the Beijing Medical and Health Industry Investment Fund, marking another round of financing for Yiming Biotech after the C+ round in April 2023.
This round of financing will be used to further support the construction of Yimeng Bio's ATMPs CDMO commercial production base, promote technological iteration, enhance the service capabilities of the CDMO global service network, strengthen the company’s core competitiveness in the ATMPs drug technology sector, and build a comprehensive CDMO service platform from preclinical research, product development to commercial production.
Innovent Biologics to Merge with Ikena in Reverse to Develop OX40-Targeted Innovative Drug, Raising $75 Million
On December 23, Nasdaq biopharmaceutical company Ikena Oncology (IKNA.US) and Inmagene announced that they have entered into a definitive merger agreement. Inmagene will be acquired by Ikena through a reverse merger. This merger will generate $175 million in proceeds, including a $75 million oversubscribed PIPE financing. Ikena has reached subscription agreements with new investors such as Deep Track Capital, Foresite Capital, and RTW Investments. Additionally, Ikena's existing shareholders, including BVF Partners LP, Blue Owl Healthcare Opportunities, Omega Funds, and OrbiMed, also participated in this PIPE investment.
The merged company will focus on developing the monoclonal antibody (mAb) IMG-007 targeting OX40 for the treatment of atopic dermatitis. The merged company plans to operate under the name "ImageneBio" and trade on NASDAQ under the ticker symbol “IMA”.
Anges Biotech Completes $120 Million Series C Financing, Focusing on Severe Bone Disease R&D
On December 11, AngesBio announced the completion of a US$120 million Series C financing round, led by Bain Capital, with new investors Janus Henderson, and existing shareholders Orbimed, Samsara BioCapital, Yonghua Capital, Yonhua Investment, Legend Capital, and Liche Investment.
The proceeds from this financing will be used to support Anjisheng's new drug development pipeline, including AGA2118 (a bispecific antibody targeting sclerostin and DKK1), AGA2115, AGA111 (recombinant human bone morphogenetic protein 6 (BMP-6) for injection), and other research projects. The company is committed to developing differentiated and innovative therapeutic solutions for severe diseases in the fields of bones, joints, and muscles.
Farbexintian Completes A2 Round Financing of 100 Million Yuan, Strengthening Molecular Imaging and Radiopharmaceuticals R&D
On December 9, Faber Genesis announced the completion of its A2 round of financing worth hundreds of millions. This round of financing was led by Beijing Tongfu Innovation Industrial Investment Fund Partnership (Limited Partnership), managed by China Nuclear Industry Fund Management Co., Ltd.
The funds from this round of financing will be mainly used for the research and development of FabreXin's existing pipeline and the construction of a radiopharmaceutical industrialization base.
Qiheshengke Completes Over 200 Million Yuan in Series A Financing, Accelerating R&D and Industrialization of Gene Editing Technology
On December 2, Qihex Biotech announced the completion of an A-round financing exceeding 200 million RMB. This round of financing was led by the Beijing Medical and Health Industry Investment Fund, with Chang Development Group and Mingzhe Assets participating as co-investors, while the existing shareholder Chen De Capital continued to support.
The funds raised will be mainly used for the in-depth research and development of the company's gene editing technology, the optimization and expansion of the gene editing product pipeline, and the commercialization platform implementation, further enhancing the company's core competitiveness and market influence in the biotechnology industry.
Yafei Biotech Completes Over 400 Million Yuan in Series B2 Financing, Accelerating New Drug Development
On December 2, Yafei Biotechnology, the parent company of Affinity, announced that it had completed its B2 round of financing, with investment in this round exceeding 400 million RMB. This round of financing was led by SDIC Venture Capital, with participation from Huachuang Capital, Hongcheng Investment, Guozheng Investment, Guosheng Capital, Hongfu Assets, Anxin Guosheng Micro-Core Fund, Guoyuan Innovation Investment, and Hongyao Sci-Tech Innovation, among other well-known investment institutions. CITIC Securities served as the financial advisor for this round.
This round of financing will provide strong momentum for Affinity in the global innovative drug clinical research process, accelerating the research and development of the company's technology platform and drugs to meet the urgent clinical needs in the field of cancer treatment.
